Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF
COVID-19, remdesivir, antiviral, treatment, mortality
HASANOĞLU, İMRAN; GÜNER, HATİCE RAHMET; ÇELİK, İLHAMİ; KANAT, FİKRET; BATIREL, AYŞE; DİZMAN, GÜLÇİN TELLİ; EREN, ESMA ERYILMAZ; SEVGİ, DİLEK YILDIZ; BOZKURT, İLKAY; YAŞAR, KADRİYE KART; ŞENOĞLU, SEVTAP; KAZAK, ESRA; KARAALİ, RIDVAN; ÇELİKBAŞ, AYSEL KOCAGÜL; and PULLUKÇU, HÜSNÜ
"Remdesivir treatment for patients with moderate to severe COVID-19,"
Turkish Journal of Medical Sciences: Vol. 52:
4, Article 2.
Available at: https://journals.tubitak.gov.tr/medical/vol52/iss4/2